Back to search results

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Abroad (travel likely)RecruitingPHASE1

Conditions

Metastatic Malignant Solid Neoplasm

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

    Contact: Study coordinator (Fred Hutch Intake) · hutchdoc@fredhutch.org · 206-606-1024
    Contact: Principal Investigator (Elena Chiorean)
Study leads

  • Elena Chiorean

    Principal Investigator

    Fred Hutch/University of Washington Cancer Consortium

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)